Fouad Namouni, head of R&D at Blueprint Medicines, discusses how dual blockade of a single target could push the tyrosine kinase inhibitor envelope.

中文翻译：

---

第四代 EGFR 抑制剂是否展示了激酶抑制剂的未来？

Blueprint Medicines 的研发主管 Fouad Namouni 讨论了单一靶点的双重阻断如何推动酪氨酸激酶抑制剂的包膜。